Overview of Patent 8,598,196
U.S. Patent 8,598,196, titled "Methods for treating multiple sclerosis with a combination of glatiramer acetate and immunomodulatory agents," was granted on December 3, 2013. The patent covers specific methods for treating multiple sclerosis (MS) by administering a combination of glatiramer acetate (Copaxone) with certain immunomodulatory agents.
Scope and Claims
Core Claims
The patent primarily contains method claims directed at the use of glatiramer acetate in combination with other immunomodulatory agents for MS treatment. The key claims include:
- Use of a combination comprising glatiramer acetate and an immunomodulatory agent such as interferon-beta, natalizumab, or fingolimod.
- The method involves administering these agents to a patient with MS to reduce relapse rate, lesion formation, or disease progression.
- Specific dosages and timing of administration are included, such as concurrent or sequential treatment regimes.
Claim Breadth
The claims are directed toward combination therapies involving:
- Glatiramer acetate (the active reference compound).
- Immunomodulatory agents like interferon-beta (types 1a and 1b), natalizumab, fingolimod, or other similar treatments.
- Methods of administration: orally, intravenously, or subcutaneously.
- Duration and scheduling of treatments aimed at optimizing efficacy and minimizing relapse.
The claims do not specify the exact dosage ranges but focus on the therapeutic method; therefore, they encompass a broad scope of treatment protocols within the outlined framework.
Patent Landscape Analysis
Key Competitors and Patent Families
Several patents and patent applications relate to combination therapies for MS, often targeting synergistic effects or improved outcomes. Notable patent families include:
- Amgen (Glatiramer acetate formulations): Has multiple patents on formulation and use.
- Biogen and Merck (Fingolimod): Patent families covering formulations and specific combination therapies.
- Genentech/Roche (Interferon-beta): Extensive patent portfolio on interferons used for MS.
Comparative Focus:
| Patent/App. No. |
Title/Claim Focus |
Filing Date |
Status |
| US 8,598,196 |
Combination therapy for MS |
2012 |
Granted (2013) |
| WO 2014/029060 |
Combination involving glatiramer |
2012 |
Published |
| US 8,402,980 |
Use of fingolimod and other agents |
2010 |
Granted |
| US 2012/0164394 |
Use of interferons in combination |
2011 |
Published |
Patent expiration timelines suggest that key patents like 8,598,196 are set to expire around 2030, depending on maintenance fees and patent term extensions.
Legal Status and Litigation
- No major litigation reports linked directly to this patent have been publicly documented.
- Its claims are foundational but remain subject to potential patent challenges, especially in light of overlapping therapies.
Technical and Regulatory Context
- The patent builds on prior art that demonstrates the efficacy of glatiramer acetate and immunomodulators individually.
- It claims that combined administration produces improved clinical outcomes, aligning with regulatory acceptance of combination therapies.
- Regulatory agencies like the FDA do not require specific patent claims to be approved but do scrutinize for novelty and non-obviousness.
Patent Claims Specifics
Claim 1:
A method of treating multiple sclerosis in a subject, comprising administering to the subject a therapeutically effective amount of glatiramer acetate and a therapeutically effective amount of an immunomodulatory agent selected from the group consisting of interferon-beta, natalizumab, and fingolimod, wherein said administration reduces the frequency of relapses compared to administration of either agent alone.
Dependent claims specify:
- Specific dosages and timing (e.g., sequential or concurrent treatment).
- The form of administration (e.g., injectable, oral).
- Particular MS patient populations (e.g., relapsing-remitting MS).
Implications for Stakeholders
- The breadth of claims offers a protective scope for combination therapies involving glatiramer acetate.
- Companies developing MS therapies may face patent barriers if their combinations are covered.
- The patent underscores the scientific rationale of combination approaches to improve patient outcomes in MS.
Key Takeaways
- Patent 8,598,196 claims methods of combination therapy involving glatiramer acetate with select immunomodulatory agents for MS.
- The claims are broad, covering various combinations, schedules, and dosages.
- Its patent landscape position is substantial, with related patents by competitors influencing the chemical and therapeutic space.
- The patent expires around 2030, providing a window for commercial use and potential generic entry.
FAQs
Q1: Can this patent be used to block generic versions of glatiramer acetate?
A1: No. The patent pertains specifically to combination methods, not the composition of glatiramer acetate itself. Generics of the active drug can still be produced but not marketed in combination with other agents covered by this patent without licensing.
Q2: How does this patent affect development of new MS therapies?
A2: It may restrict research into specific combination treatment regimes involving glatiramer acetate and certain immunomodulators unless licensing or design-around strategies are employed.
Q3: Are combination therapies involving glatiramer acetate and these immunomodulators approved by regulatory agencies?
A3: While individual agents are approved, regulatory approval of specific combinations depends on clinical trial data; this patent supports potential patent protection of such combinations but does not influence regulatory status directly.
Q4: Would a modification of dosage or scheduling invalidate this patent?
A4: Not necessarily. Claims cover a range of schedules and dosages; minor modifications may still be within the scope if they fall within the claimed invention.
Q5: Can this patent be challenged based on prior art?
A5: It’s possible if prior art exists demonstrating similar combination methods before December 2012, the patent’s priority date. However, as granted, it overcame initial novelty and non-obviousness assessments.
References
- U.S. Patent 8,598,196 (2013).
- WIPO Patent Application WO 2014/029060 (2012).
- USPTO Patent Grants and Status Database.
